Canada · Delayed Price · Currency is CAD Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of CAD 508.95 billion. The enterprise value is 575.42 billion.
| Market Cap | 508.95B |
| Enterprise Value | 575.42B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.92% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 81.53% |
| Float | 2.46B |
Valuation Ratios
The trailing PE ratio is 112.95 and the forward PE ratio is 16.61.
| PE Ratio | 112.95 |
| Forward PE | 16.61 |
| PS Ratio | 5.38 |
| PB Ratio | 8.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.31 |
| P/OCF Ratio | 17.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of 25.23.
| EV / Earnings | 127.70 |
| EV / Sales | 6.09 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 17.26 |
| EV / FCF | 25.23 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.28.
| Current Ratio | 1.32 |
| Quick Ratio | 0.74 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | 1.84 |
| Debt / FCF | 3.36 |
| Interest Coverage | 13.47 |
Financial Efficiency
Return on equity (ROE) is 6.96% and return on invested capital (ROIC) is 14.05%.
| Return on Equity (ROE) | 6.96% |
| Return on Assets (ROA) | 11.87% |
| Return on Invested Capital (ROIC) | 14.05% |
| Return on Capital Employed (ROCE) | 23.01% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.28M |
| Profits Per Employee | 60,892 |
| Employee Count | 75,000 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, Merck & Co. has paid 3.95 billion in taxes.
| Income Tax | 3.95B |
| Effective Tax Rate | 46.72% |
Stock Price Statistics
The stock price has increased by +81.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +81.06% |
| 50-Day Moving Average | 31.58 |
| 200-Day Moving Average | 27.30 |
| Relative Strength Index (RSI) | 47.81 |
| Average Volume (20 Days) | 11,477 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.49 |
Income Statement
In the last 12 months, Merck & Co. had revenue of CAD 94.53 billion and earned 4.51 billion in profits. Earnings per share was 1.81.
| Revenue | 94.53B |
| Gross Profit | 71.75B |
| Operating Income | 33.35B |
| Pretax Income | 8.45B |
| Net Income | 4.51B |
| EBITDA | 41.00B |
| EBIT | 33.35B |
| Earnings Per Share (EPS) | 1.81 |
Balance Sheet
The company has 10.14 billion in cash and 76.56 billion in debt, with a net cash position of -66.42 billion.
| Cash & Cash Equivalents | 10.14B |
| Total Debt | 76.56B |
| Net Cash | -66.42B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 59.62B |
| Book Value Per Share | 24.12 |
| Working Capital | 12.71B |
Cash Flow
In the last 12 months, operating cash flow was 28.36 billion and capital expenditures -5.54 billion, giving a free cash flow of 22.81 billion.
| Operating Cash Flow | 28.36B |
| Capital Expenditures | -5.54B |
| Depreciation & Amortization | 7.67B |
| Net Borrowing | 26.59B |
| Free Cash Flow | 22.81B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.90%, with operating and profit margins of 35.28% and 4.77%.
| Gross Margin | 75.90% |
| Operating Margin | 35.28% |
| Pretax Margin | 8.94% |
| Profit Margin | 4.77% |
| EBITDA Margin | 43.37% |
| EBIT Margin | 35.28% |
| FCF Margin | 24.08% |
Dividends & Yields
This stock pays an annual dividend of 0.77, which amounts to a dividend yield of 2.37%.
| Dividend Per Share | 0.77 |
| Dividend Yield | 2.37% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 261.52% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.92% |
| Shareholder Yield | 4.28% |
| Earnings Yield | 0.89% |
| FCF Yield | 4.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Merck & Co. has an Altman Z-Score of 3.6 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 4 |